Vaccinex logo
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
April 02, 2024 08:30 ET | Vaccinex, Inc.
Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.
Vaccinex logo
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 27, 2024 08:30 ET | Vaccinex, Inc.
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Vaccinex logo
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
October 26, 2023 09:30 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a...
Figure 1
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
October 13, 2023 07:00 ET | Tiziana Life Sciences Ltd.
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)Foralumab to advance into Phase 2 human...
tiziana-logo.png
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
October 11, 2023 07:00 ET | Tiziana Life Sciences Ltd.
Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes
ORION BIOTECHNOLOGY
ORION BIOTECHNOLOGY RECEIVES FUNDING TO ADVANCE ITS LEAD GPCR-TARGETED THERAPEUTIC
November 04, 2021 11:03 ET | Orion Biotechnology Canada Ltd.
Ottawa, Canada, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel...
AZ Logo.png
AZTherapies Completes COGNITE Phase 3 Alzheimer’s Clinical Trial; Top-Line Data Readout Expected in First Quarter of 2021
November 18, 2020 08:35 ET | AZTherapies, Inc.
Last Patient/Last Visit completed on November 13th enabling full clinical database lock BOSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical...
AZ Logo.png
AZTherapies Doses First Patient in Phase 2a Study of ALZT-OP1a in Amyotrophic Lateral Sclerosis (ALS)
September 09, 2020 08:34 ET | AZTherapies, Inc.
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the dosing of the first...
AZ Logo.png
AZTherapies Announces the Appointment of Drs. Robert Malenka, Adam Boxer, Vijay Kuchroo and Megan Levings, to Scientific Advisory Board
August 11, 2020 08:35 ET | AZTherapies, Inc.
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the expansion of its...
AZ Logo.png
AZTherapies Strengthens Board of Directors & Business Advisory Board with New Appointments
July 22, 2020 08:35 ET | AZTherapies, Inc.
Noah Gottdiener of Duff & Phelps and Thierry Porté of J.C. Flowers & Co. join BOD Retired Eli Lilly executive Joseph B. Kelley joins Business Advisory Board BOSTON, July 22, 2020 (GLOBE...